The safety of statins in clinical practice.
Jane Armitage
https://pubmed.ncbi.nlm.nih.gov/17559928/Actively Recruiting
Led by Korea University Anam Hospital · Updated on 2025-04-27
2000
Participants Needed
1
Research Sites
21 weeks
Total Duration
Researchers are evaluating two cholesterol-lowering approaches to see which has a lower risk of causing new-onset diabetes in people with prediabetes and established atherosclerotic cardiovascular disease ASCVD. This multicenter, randomized study involves 2,000 non-diabetic participants and compares a combination of pitavastatin and ezetimibe with high-intensity statin therapy using rosuvastatin. The main goal is to measure new cases of diabetes over a 36-month follow-up, along with other cardiovascular outcomes and changes in blood markers. Participants will be randomly assigned to receive either a fixed-dose single-pill combination of pitavastatin 4 mg plus ezetimibe 10 mg or rosuvastatin 20 mg alone. The study lasts up to 3 years with ongoing treatment. Both treatment strategies aim to manage cholesterol levels while monitoring the risk of developing diabetes. The trial is organized by Korea University Anam Hospital and is conducted without masking, meaning both participants and researchers know the treatment given. Throughout the study, participants will undergo regular assessments including blood tests for fasting glucose, HbA1c, and insulin resistance, as well as monitoring for cardiovascular events like heart attacks and strokes. Researchers will track adherence to a cholesterol-lowering diet and collect safety data. The primary outcome is the occurrence of new diabetes cases meeting standard diagnostic criteria, while secondary outcomes include cardiovascular health and cholesterol changes. Participants health will be followed for up to three years to evaluate these outcomes.
CONDITIONS
Comparison of Pitavastatin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes Mellitus
C
Cheol Woong Yu
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Korea University Anam Hospital
Lead Sponsor
Daewon Pharmaceutical Co., Ltd.
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 3 years
Participants receive either a fixed dose single-pill combination of pitavastatin 4mg plus ezetimibe 10mg or rosuvastatin 20mg to prevent new-onset diabetes mellitus.
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Jane Armitage
https://pubmed.ncbi.nlm.nih.gov/17559928/François Mach, Kausik K Ray, Olov Wiklund...
https://pubmed.ncbi.nlm.nih.gov/29718253/Borja Ibanez, Stefan James, Stefan Agewall...
https://pubmed.ncbi.nlm.nih.gov/28886621/Hertzel C Gerstein, Pasqualina Santaguida, Parminder Raina...
https://pubmed.ncbi.nlm.nih.gov/17601626/American Diabetes Association
https://pubmed.ncbi.nlm.nih.gov/30559228/Aleesa A Carter, Tara Gomes, Ximena Camacho...
https://pubmed.ncbi.nlm.nih.gov/23704171/Frank B Hu, Meir J Stampfer, Steven M Haffner...
https://pubmed.ncbi.nlm.nih.gov/12087009/Wilson C Y Yip, Ivana R Sequeira, Lindsay D Plank...
https://pubmed.ncbi.nlm.nih.gov/29165385/François Mach, Colin Baigent, Alberico L Catapano...
https://pubmed.ncbi.nlm.nih.gov/31504418/Doralisa Morrone, William S Weintraub, Peter P Toth...
https://pubmed.ncbi.nlm.nih.gov/22410123/Korea University Anam Hospital
Lead Sponsor
Daewon Pharmaceutical Co., Ltd.
Collaborating Sponsor